Company profile: Emalex Biosciences
1.1 - Company Overview
Company description
- Provider of biotech therapies for central nervous system disorders, developing Ecopipam, a novel investigational D1 receptor dopamine blocker targeting Tourette syndrome, and conducting an FDA-regulated Phase 3 trial (EBS-101) in children, adolescents, and adults with Tourette’s. Also pursuing investigational treatments for childhood-onset fluency disorder (stuttering) in adults.
Products and services
- Ecopipam: An investigational compound engineered to treat Tourette syndrome by blocking dopamine at the D1 receptor, developed for central nervous system disorders
- Investigational Therapies for Childhood-Onset Fluency Disorder: Adult-focused research developing treatments for stuttering in adults, addressing the lack of FDA-approved options for this central nervous system condition
- Phase 3 Clinical Trial for Tourette Syndrome: An FDA-regulated study evaluating the safety and efficacy of Ecopipam (EBS-101) in children, adolescents, and adults with Tourette’s
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Emalex Biosciences
ADRx
HQ: United States
Website
- Description: Provider of a structure-based drug discovery platform that transforms atomic structures into small molecule therapies for protein aggregation diseases, targeting pathological protein structures. Develops small molecule modulators of protein-protein interactions, including amyloids and biomolecular condensates, and advances drug candidates for Alzheimer’s, systemic amyloidosis, ovarian cancer, ALS, and Parkinson’s.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADRx company profile →
Auspex Pharma
HQ: United States
Website
- Description: Provider of development and commercialization of novel medicines for orphan diseases, with product candidates addressing unmet needs in hyperkinetic movement disorders such as chorea associated with Huntington's disease; also a deuteration company developing therapeutics for depressive disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Auspex Pharma company profile →
CervoMed
HQ: United States
Website
- Description: Provider of clinical-stage research and development focused on discovering therapies for brain degenerative illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CervoMed company profile →
Nido Bio
HQ: United States
Website
- Description: Provider of precision medicines for severe neurological diseases, with a clinical-stage program, NIDO-361, targeting Spinal Bulbar Muscular Atrophy (SBMA) by addressing both toxic gain of function and loss of function associated with the disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nido Bio company profile →
Avid Radiopharmaceuticals
HQ: United States
Website
- Description: Provider of molecular imaging agents to aid detection and monitoring of chronic human diseases. Products include FDA-approved PET imaging agents: Amyvid for detecting beta-amyloid plaques in the brain and Tauvid for detecting tau pathology in patients evaluated for Alzheimer's disease. Based in Philadelphia, PA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avid Radiopharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Emalex Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Emalex Biosciences
2.2 - Growth funds investing in similar companies to Emalex Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Emalex Biosciences
4.2 - Public trading comparable groups for Emalex Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →